Hong Kong · Delayed Price · Currency is HKD Ascentage Pharma Group International Earnings Call Transcripts
Fiscal Year 2026
-
Two novel products are commercialized in China, with multiple global Phase III trials underway for lead assets targeting hematologic malignancies. Recent clinical data show strong efficacy and safety, and U.S. commercialization is planned for 2028, with NDA filings expected next year.
Fiscal Year 2025
-
Revenue grew 90% year-over-year to $82.1M, driven by olverembatinib and lisaftoclax launches, with strong commercial expansion and a $353.2M year-end cash balance. Multiple global phase III trials are advancing, with NDA filings targeted for 2027.
-
Pivotal phase II data for lisaftoclax in high-risk CLL/SLL showed strong efficacy and safety, while updated results in AML/MDS and the launch of global phase III trials in MDS and ALL highlight broad clinical progress. Olverembatinib demonstrated best-in-class activity in CML and ALL, and the pipeline features novel protein degraders and EED inhibitors.
Fiscal Year 2024
-
2024 saw transformational growth with a 342% revenue increase, driven by Takeda's partnership and strong olverembatinib sales. Expanded NRDL coverage and a successful Nasdaq IPO further strengthened the outlook, with robust late-stage pipeline progress and global commercialization plans.